

# **Certificate of Analysis**

Print Date: Jan 14<sup>th</sup> 2016

www.tocris.com

Product Name: MK 0343 Catalog No.: 4415 Batch No.: 1

CAS Number: 233275-76-8

IUPAC Name: 7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(1-methyl-1*H*-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazo[4,3-*b*]pyridazine

## 1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula:  $C_{19}H_{17}F_2N_7O$ 

**Batch Molecular Weight:** 397.38 **Physical Appearance:** White solid

Solubility: DMSO to 100 mM

ethanol to 50 mM

Storage: Store at +4°C

**Batch Molecular Structure:** 

## 2. ANALYTICAL DATA

**TLC:**  $R_f = 0.18$  (Ethyl acetate:Petroleum ether [2:1])

Found

HPLC: Shows 99.8% purity

1H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 57.43 4.31 24.67

4.26

24.61

57.17



## **Product Information**

Print Date: Jan 14th 2016

www.tocris.com

Product Name: MK 0343 Catalog No.: 4415 Batch No.: 1

CAS Number: 233275-76-8

**IUPAC Name:** 7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(1-methyl-1*H*-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazo[4,3-b]pyridazine

## **Description:**

Subtype-selective GABA<sub>A</sub> partial agonist (K<sub>i</sub> values are 0.21, 0.22, 0.23 and 0.40 for  $\alpha 3$ ,  $\alpha 1$ ,  $\alpha 5$  and  $\alpha 2$  respectively); occupies the benzodiazepine site of GABAA receptors. Displays greater agonist efficacy at a compared to a 1. Exhibits anxiolytic and non-sedating properties in rodent models. Brain penetrant.

## **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>19</sub>H<sub>17</sub>F<sub>2</sub>N<sub>7</sub>O Batch Molecular Weight: 397.38 Physical Appearance: White solid

Minimum Purity: >99%

## **Batch Molecular Structure:**

Storage: Store at +4°C

## Solubility & Usage Info:

DMSO to 100 mM ethanol to 50 mM

## Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### References:

de Haas et al (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA<sub>A</sub> α<sub>2,3</sub> subtype-selective agonist, compared to lorazepam and placebo in healthy male volunteers. J.Psychopharmacol. 22 24. PMID: 18187530.

Atack et al (2010) Benzodiazepine binding site occupancy by the novel GABA<sub>△</sub> receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2*H*-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. J.Pharmacol.Exp.Ther. 332 17.

Atack et al (2011) MRK-409 (MK-0343), a GABA<sub>A</sub> receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J.Psychopharmacol. 25 314. PMID: 20147571.

Tel: +44 (0)1235 529449

www.tocris.com/distributors Tel:+1 612 379 2956